source
- EyePoint shares tumble as Durayvu misses primary goal in wet AMD trialEyePoint, a Boston biotech, saw its market value drop by nearly $1 billion after its lead candidate Durayvu failed to demonstrate non-inferiority to aflibercept in a pivotal phase 3 trial for wet a…
- EyePoint’s Phase 3 eye drug falls short of Eylea, stock tumbles 70%EyePoint reported that its experimental treatment for wet age-related macular degeneration did not meet the efficacy endpoints in a Phase 3 trial when compared with the current standard, Eylea. The…